NEW YORK (GenomeWeb) – Protagen said today it has entered a collaboration with the Gustave Roussy Institute of Oncology to identify biomarkers for immune system-related side effects in cancer patients treated with checkpoint inhibitors.

Under the collaboration, the parties will use Protagen's SeroTag platform, which simultaneously measures autoantibody levels for thousands of antigens, to test cancer immunotherapy patients for markers linked to immune-related adverse events (irAEs) and, ultimately, develop a risk-profiling test for patients undergoing immunotherapy.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.

CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.

The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.

In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.

Jul
12
Sponsored by
Canon BioMedical

This webinar will discuss a project that is analyzing the “Human Brainome” – genome, transcriptome, proteome, and phenome interaction data -- to gain insights into Alzheimer’s disease pathogenesis.